EP1181306A4 - Compounds and methods for regulating apoptosis, and methods of making and screening for compounds that regulate apoptosis - Google Patents

Compounds and methods for regulating apoptosis, and methods of making and screening for compounds that regulate apoptosis

Info

Publication number
EP1181306A4
EP1181306A4 EP00935853A EP00935853A EP1181306A4 EP 1181306 A4 EP1181306 A4 EP 1181306A4 EP 00935853 A EP00935853 A EP 00935853A EP 00935853 A EP00935853 A EP 00935853A EP 1181306 A4 EP1181306 A4 EP 1181306A4
Authority
EP
European Patent Office
Prior art keywords
compounds
methods
apoptosis
screening
making
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00935853A
Other languages
German (de)
French (fr)
Other versions
EP1181306A1 (en
Inventor
Xiao-Mai Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apoptosis Technology Inc
Original Assignee
Apoptosis Technology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apoptosis Technology Inc filed Critical Apoptosis Technology Inc
Publication of EP1181306A1 publication Critical patent/EP1181306A1/en
Publication of EP1181306A4 publication Critical patent/EP1181306A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
EP00935853A 1999-05-28 2000-05-30 Compounds and methods for regulating apoptosis, and methods of making and screening for compounds that regulate apoptosis Withdrawn EP1181306A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13678399P 1999-05-28 1999-05-28
US136783P 1999-05-28
PCT/US2000/011864 WO2001010888A1 (en) 1999-05-28 2000-05-30 Compounds and methods for regulating apoptosis, and methods of making and screening for compounds that regulate apoptosis

Publications (2)

Publication Number Publication Date
EP1181306A1 EP1181306A1 (en) 2002-02-27
EP1181306A4 true EP1181306A4 (en) 2003-06-18

Family

ID=22474341

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00935853A Withdrawn EP1181306A4 (en) 1999-05-28 2000-05-30 Compounds and methods for regulating apoptosis, and methods of making and screening for compounds that regulate apoptosis

Country Status (5)

Country Link
EP (1) EP1181306A4 (en)
JP (1) JP2003506071A (en)
AU (1) AU765983B2 (en)
CA (1) CA2373814A1 (en)
WO (1) WO2001010888A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
JP4142356B2 (en) 2001-07-05 2008-09-03 オイクロ ヨーロピアン コントラクト リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト PP2C substrate
EP1273654A1 (en) * 2001-07-05 2003-01-08 Schering Aktiengesellschaft BAD as substrate for PP2C
JPWO2003018058A1 (en) * 2001-08-22 2004-12-09 横田　充弘 Cardiomyocyte apoptosis inhibitor
WO2003042239A1 (en) * 2001-11-12 2003-05-22 Stichting Sanquin Bloedvoorziening Peptides inhibiting signaling by ras-like gtpases
PT1343013E (en) * 2002-03-07 2006-09-29 Pasteur Institut METHODS FOR THE SCREENING OF COMPOUND MODULATORS OF APOPTOSE COMPOUNDS IDENTIFIED BY THESE METHODS AND USES THESE COMPOUNDS AS THERAPEUTIC AGENTS
WO2003082322A1 (en) * 2002-03-28 2003-10-09 Medvet Science Pty. Ltd. A method of modulating cellular activity
JP2004018524A (en) * 2002-06-13 2004-01-22 Eucro European Contract Research Gmbh & Co Kg Method for treating arteriosclerosis
EP1661912A1 (en) * 2004-11-29 2006-05-31 Xigen S.A. Fusion protein comprising a BH3-domain of a BH3-only protein
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007035494A2 (en) * 2005-09-16 2007-03-29 The Regents Of The University Of California Inducing expression of puma to reduce joint inflammation in the treatment of arthritis
CA2681808A1 (en) * 2007-03-20 2008-09-25 The Walter And Eliza Hall Institute Of Medical Research Method of screening
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
CA2807036C (en) 2010-10-14 2018-01-16 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
EA201501080A1 (en) 2013-06-26 2016-07-29 Ксижен Инфлемейшн Лтд. NEW APPLICATIONS OF POSSIBLE ABILITIES TO PUNCH THE PEPTIDE INHIBITORS IN THE CELL OF JNK SIGNAL TRANSFORMATION TREATMENT FOR THE TREATMENT OF VARIOUS DISEASES

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965703A (en) * 1996-09-20 1999-10-12 Idun Pharmaceuticals Human bad polypeptides, encoding nucleic acids and methods of use

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
BOWIE J.U. ET AL: "Deciphering the message in protein sequences: tolerance to amino acid substitutions.", SCIENCE, vol. 247, no. 4948, 16 March 1990 (1990-03-16), NEW YORK, NY, US, pages 1306 - 1310 *
BURGESS W.H. ET AL: "POSSIBLE DISSOCIATION OF THE HEPARIN-BINDING AND MITOGENIC ACTIVITIES OF HEPARIN-BINDING (ACIDIC FIBROBLAST) GROWTH FACTOR-1 FROM ITS RECEPTOR-BINDING ACTIVITIES BY SITE-DIRECTED MUTAGENESIS OF A SINGLE LYSINE RESIDUE.", JOURNAL OF CELL BIOLOGY, November 1990 (1990-11-01), NEW YORK, NY, US, XP002074068 *
DATTA SANDEEP ROBERT ET AL: "14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation.", MOLECULAR CELL, vol. 6, no. 1, July 2000 (2000-07-01), pages 41 - 51, XP002238397, ISSN: 1097-2765 *
DATTA SANDEEP ROBERT ET AL: "Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery.", CELL, vol. 91, no. 2, 1997, pages 231 - 241, XP002238395, ISSN: 0092-8674 *
GILLIES S.D.; WESOLOWSKI J.S.: "ANTIGEN BINDING AND BIOLOGICAL ACTIVITIES OF ENGINEERED MUTANT CHIMERIC ANTIBODIES WITH HUMAN TUMOR SPECIFICITIES.", HUMAN ANTIBODIES AND HYBRIDOMAS, vol. 1, no. 1, 1990, pages 47 - 54, XP002050448 *
HARADA HISASHI ET AL: "Phosphorylation and inactivation of BAD by mitochondria-anchored protein kinase A.", MOLECULAR CELL, vol. 3, no. 4, April 1999 (1999-04-01), pages 413 - 422, XP002238394, ISSN: 1097-2765 *
LAZAR E. ET AL: "TRANSFORMING GROWTH FACTOR ALPHA MUTATION OF ASPARTIC ACID 47 AND LEUCINE 48 RESULTS IN DIFFERENT BIOLOGICAL ACTIVITIES", MOLECULAR AND CELLULAR BIOLOGY, vol. 8, no. 3, 1988, pages 1247 - 1252 *
OTTILIE S ET AL: "Dimerization properties of human BAD. Identification of a BH-3 domain and analysis of its binding to mutant BCL-2 and BCL-XL proteins.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. UNITED STATES 5 DEC 1997, vol. 272, no. 49, 5 December 1997 (1997-12-05), pages 30866 - 30872, XP002238393, ISSN: 0021-9258 *
See also references of WO0110888A1 *
TAO M.-H.; MORRISON S.L.: "STUDIES OF AGLYCOSYLATED CHIMERIC MOUSE-HUMAN IGG", JOURNAL OF IMMUNOLOGY, vol. 143, no. 8, 15 October 1989 (1989-10-15), BALTIMORE, MD, US, pages 2595 - 2601, XP000984625 *
ZHA JIPING ET AL: "Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X-L.", CELL, vol. 87, no. 4, 1996, pages 619 - 628, XP002238396, ISSN: 0092-8674 *
ZHOU XIAO-MAI ET AL: "Growth factors inactivate the cell death promoter BAD by phosphorylation of its BH3 domain on Ser155.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 32, 11 August 2000 (2000-08-11), pages 25046 - 25051, XP002238398, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
CA2373814A1 (en) 2001-02-15
EP1181306A1 (en) 2002-02-27
WO2001010888A1 (en) 2001-02-15
AU5125300A (en) 2001-03-05
AU765983B2 (en) 2003-10-09
JP2003506071A (en) 2003-02-18

Similar Documents

Publication Publication Date Title
EP1181306A4 (en) Compounds and methods for regulating apoptosis, and methods of making and screening for compounds that regulate apoptosis
MXPA03007960A (en) Compounds and methods for the treatment of urogenital disorders.
AP2004003135A0 (en) Compounds that modulate PPAR activity and methods for their preparation
ZA993753B (en) Tapered prosthetic spinal disc nucleus.
AU2001293189A1 (en) Compositions and methods for regulating apoptosis
AU2396000A (en) Treatment of hyperproliferative disorders using casein kinase
EP1485398A4 (en) Methods of screening for compounds that modulate hormone receptor activity
ZA9710419B (en) Compositions and methods for regulating apoptosis
AU2384500A (en) Compounds, methods of screening and methods of treatment for central and peripheral nervous system disorders
AU2106001A (en) Methods and compositions for screening for angiogenesis modulating compounds
TW345297U (en) Adjusting secure seat for sound-wire of drum
AU9763098A (en) Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds
AU2826099A (en) Heterocyclic compounds regulating clotting
NO20012106L (en) Means for the treatment of disorders of bone metabolism
HUP0201647A3 (en) Screening methods for compounds that affect melanogenesis
HK1039333A1 (en) 3-tetrahydropyridin-4-yl indoles for treatment of psychotic disorders
IL133510A0 (en) Selective regulation of adenovirus production
IL137371A0 (en) Gene expression methods for screening compounds
DE69918953D1 (en) COMPOSITION OF OLIGOSACCHARIDES FOR REGULATING APOPTOSIS
AU2001243220A1 (en) Methods of screening for compounds that modulate blood vessel formation
EP1425020A4 (en) Methods and compositions for treating apoptosis associated disorders
AU2002353369A1 (en) Anti-pirate method for the distribution of digital content
AU2003206594A8 (en) Screening for modulators of pkng activity
GB0128793D0 (en) Screening method for compounds that modulate neuronal activity
AU5278199A (en) Protein for regulating apoptosis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011127

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07K 14/47 B

Ipc: 7G 01N 33/50 B

Ipc: 7C 07K 1/13 B

Ipc: 7C 07K 14/00 B

Ipc: 7C 07K 1/14 B

Ipc: 7G 01N 33/53 B

Ipc: 7C 07K 1/00 A

Ipc: 7C 12P 21/00 B

Ipc: 7C 12P 21/02 B

A4 Supplementary search report drawn up and despatched

Effective date: 20030506

17Q First examination report despatched

Effective date: 20050203

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20071122